查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654403

胜肽類抗生素市場規模、佔有率、趨勢分析報告：按疾病、給藥途徑、產品、分銷管道、地區、細分預測，2025-2030 年

Peptide Antibiotics Market Size, Share & Trends Analysis Report By Disease (Skin Infection, HABP/VABP), By Route of Administration (Injectable, Oral), By Product, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肽類抗生素市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，全球胜肽類抗生素市場規模預計到2030年將達到66.4億美元，2025年至2030年期間的複合年成長率為5.1%。

由於研發活動活性化和胜肽類抗生素領域藥物核准數量增加等因素，預計市場將迎來成長機會。此外，預測期內，抗生素抗藥性病例的激增以及傳統抗生素可能產生的副作用預計也將推動市場的發展。

預計預測期內癌症和其他感染疾病的發生率不斷上升將推動成長。例如，根據美國疾病管制與預防中心的數據，2019 年美國報告了 1,752,735 例新癌症病例，同時有 599,589 人死亡。每10萬人口中，有439人新發癌症病例，146人死於癌症。此外，根據Globocan 2020的數據，英國2020年新患者457,960例，死亡人數179,648人。最常見的惡性腫瘤類型是乳癌、攝護腺癌和非何傑金氏淋巴瘤。

一些胜肽類抗生素用於治療癌症，包括非何傑金氏淋巴瘤、何傑金氏淋巴瘤和某些皮膚惡性腫瘤。根據Globocan 2020的數據，非何傑金氏淋巴瘤患者人數為544,352人，何傑金氏淋巴瘤患者人數為83,087人。預計各種現有產品的有效性將因醫生的推薦而帶來更高的收益。例如，注射用博來黴素 USP 是從鏈黴菌中分離出來的細胞毒性糖肽抗生素的混合物，用於治療睪丸癌、鱗狀細胞癌和各種淋巴瘤。

此外，預測期內市場參與企業正在進行的產品核可和採取的策略舉措預計（如合作、協作研究、產品發布和業務擴展）將推動市場成長。例如，2021年7月，艾伯維公司宣布，美國FDA核准DALVANCE用於治療從出生起的兒科患者的急性細菌性皮膚和皮膚結構感染疾病。此外，2020年7月，山德士國際有限公司宣布將向美國市場推出 Cubicin 的學名藥——達托黴素注射液 500 毫克，用於治療患有複雜皮膚和皮膚結構感染疾病以及幾種類型血流感染疾病的成年患者。

肽類抗生素市場報告重點

  • 非核醣體合成胜肽抗生素領域佔據市場主導地位，佔 2024 年全球銷售額的 72.79%。
  • 醫院藥局部門將佔據市場主導地位，到 2024 年的市場佔有率將達到 43.96%。
  • 由於感染疾病病率上升、患者群眾多等因素，預計亞太地區在預測期內將呈現最高的複合年成長率。
  • 北美肽類抗生素市場正在穩步成長，這得益於對抗擊醫院內獲得性細菌性肺炎 (HABP) 和人工呼吸器相關性細菌性肺炎 (VABP) 等複雜感染疾病的有效解決方案的需求不斷成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章胜肽抗生素市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 肽類抗生素市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析
  • 管道分析

第 4 章胜肽抗生素市場：按產品分類的估計和趨勢分析

  • 細分儀表板
  • 全球胜肽類抗生素市場：產品差異分析
  • 產品收益
  • 核醣體合成胜肽抗生素
  • 非核醣體合成胜肽抗生素

第 5 章肽類抗生素市場：按疾病、估計和趨勢分析

  • 細分儀表板
  • 全球胜肽類抗生素市場：疾病趨勢分析
  • 按疾病和收益
  • 皮膚感染疾病
  • HABP/VABP
  • 血流感染疾病
  • 其他

6. 胜肽類抗生素市場：依給藥途徑的估計與趨勢分析

  • 細分儀表板
  • 全球胜肽類抗生素市場：給藥途徑變異分析
  • 按給藥途徑分類的收益
  • 口服
  • 注射
  • 局部的
  • 其他

第7章肽類抗生素市場：按分銷管道分類的估計和趨勢分析

  • 細分儀表板
  • 全球胜肽類抗生素市場：分銷管道變化分析
  • 按分銷管道分類的收益
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 8 章胜肽類抗生素市場：按產品、疾病、給藥途徑、通路、地區進行的估計和趨勢分析

  • 區域控制面板
  • 2018-2030 年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 2024 年主要企業的市場佔有率分析
    • Pfizer Inc.
    • Teva Pharmaceuticals Industries Limited.
    • AbbVie Inc.
    • Merck &Co., Inc.
    • The Menarini Group
    • Sanofi
    • Eli Lilly and Company
    • GSK Plc.
    • NPS Pharmaceuticals
    • Xellia Pharmaceuticals
Product Code: GVR-4-68039-958-4

Peptide Antibiotics Market Growth & Trends:

The global peptide antibiotics market size is estimated to reach USD 6.64 billion by 2030, expanding at a CAGR of 5.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness growth opportunities owing to factors such as the increasing research and development activities in field of peptide antibiotics coupled with high number of drug approvals. Moreover, surge in cases of antimicrobial resistance cases and possibility of side effects from the conventional antibiotics are also expected to drive the market during the forecast period.

Increasing prevalence of cancer and other infectious diseases are expected to propel the growth over the forecast period. For instance, according to the CDC, United States reported 1,752,735 new cancer cases along with 599,589 deaths in 2019. For every 100,000 people, 439 new cases were found and 146 people died due to cancer. Further, according to Globocan 2020, U.K. had 457,960 new cases with 179,648 deaths in 2020. The most common types of malignancies were breast, prostate cancer and Non-Hodgkin's lymphoma.

There are some of the peptide antibiotics which are used to treat cancers such as, NHL, Hodgkin's lymphoma, and certain types of skin malignancies. According to Globocan 2020, there were 5,44,352 Non-Hodgkin lymphoma cases and 83,087 Hodgkin's lymphoma cases. The efficiency of various existing products is expected to result into higher revenues owing to doctor recommendations . For instance, BLEOMYCIN for injection USP is the mixture of cytotoxic glycopeptide antibiotics that is isolated from Streptomyces verticillus and is used for the treatment of testicular carcinoma, squamous cell carcinoma, and various types of lymphomas.

Moreover, ongoing product approvals and strategic initiatives undertaken by market players such as partnerships, collaborations, product launches, and expansions are expected to fuel market growth during forecast period. For instance, in July 2021, AbbVie Inc announced that the U.S. FDA approved DALVANCE for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth. Moreover, in July 2020, Sandoz International GmbH announced introduction of Daptomycin injection 500 mg, a generic version of Cubicin, in the U.S. market for the treatment of adult patients with complicated skin and skin structure infections and several type of bloodstream infections.

Peptide Antibiotics Market Report Highlights:

  • The non-ribosomal synthesized peptide antibiotics segment dominated the market and accounted for 72.79% of the global revenue in 2024.
  • The hospital pharmacies segment dominated the market with a market share of 43.96% in 2024.
  • Asia Pacific region is expected to witness the highest CAGR over the forecast period owing to factors such as, rising prevalence of infectious diseases, and availability of large patient pool
  • The North America peptide antibiotics market is growing steadily, driven by increasing demand for effective solutions to combat complex infections such as hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and disease outlook
    • 2.2.2. Route of administration and distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. Peptide Antibiotics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of microbial resistance
      • 3.2.1.2. Rising investment in R&D of novel drug
      • 3.2.1.3. Technological advancement in peptide antibiotics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Side-effects associated with drug
  • 3.3. Peptide Antibiotics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pipeline Analysis

Chapter 4. Peptide Antibiotics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Peptide Antibiotics Market: Product Movement Analysis
  • 4.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Product Revenue (USD Million)
  • 4.4. Ribosomal Synthesized Peptide Antibiotics
    • 4.4.1. Ribosomal synthesized peptide antibiotics market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Non-ribosomal Synthesized Peptide Antibiotics
    • 4.5.1. Non-ribosomal synthesized peptide antibiotics market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Peptide Antibiotics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Peptide Antibiotics Market: Disease Movement Analysis
  • 5.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Disease, Revenue (USD Million)
  • 5.4. Skin Infection
    • 5.4.1. Skin Infection market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. HABP/VABP
    • 5.5.1. HABP/VABP market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Blood Stream Infections
    • 5.6.1. Blood Stream Infections market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Peptide Antibiotics Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Peptide Antibiotics Market: Route of Administration Movement Analysis
  • 6.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Injectable
    • 6.5.1. Injectable market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Topical
    • 6.6.1. Topical market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Peptide Antibiotics Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Peptide Antibiotics Market: Distribution Channel Movement Analysis
  • 7.3. Global Peptide Antibiotics Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 7.4. Hospitals Pharmacies
    • 7.4.1. Hospitals pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Peptide Antibiotics Market: Regional Estimates & Trend Analysis By Product, Disease, Route of Administration, and Distribution Channel

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company market share analysis, 2024
    • 9.3.2. Pfizer Inc.
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Teva Pharmaceuticals Industries Limited.
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. AbbVie Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Merck & Co., Inc.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. The Menarini Group
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Sanofi
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Eli Lilly and Company
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. GSK Plc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. NPS Pharmaceuticals
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Xellia Pharmaceuticals
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 List of key distributors
  • Table 4 List of other companies
  • Table 5 List of key emerging company's/technology disruptors/innovators
  • Table 6 North America Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 8 North America Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 9 North America Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 12 U.S. Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 13 U.S. Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 16 Canada Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 17 Canada Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Mexico Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 20 Mexico Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 21 Mexico Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Europe Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 24 Europe Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 25 Europe Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 26 Europe Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 Europe Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 U.K. Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 29 U.K. Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 30 UK Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 U.K. Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Germany Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 33 Germany Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 34 Germany Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Germany Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 France Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 37 France Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 38 France Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 France Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Spain Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 41 Spain Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 42 Spain Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Spain Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Italy Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 45 Italy Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 46 Italy Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 47 Italy Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Denmark Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 49 Denmark Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 50 Denmark Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Denmark Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Sweden Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 53 Sweden Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 54 Sweden Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 Sweden Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Norway Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 57 Norway Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 58 Norway Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 Norway Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Japan Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 65 Japan Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 66 Japan Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Japan Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 China Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 69 China Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 70 China Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 China Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 India Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 73 India Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 74 India Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 India Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Australia Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 77 Australia Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 78 Australia Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 79 Australia Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 South Korea Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 81 South Korea Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 82 South Korea Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 South Korea Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 Thailand Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 85 Thailand Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 86 Thailand Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 Thailand Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 Latin America Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 89 Latin America Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 90 Latin America Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 91 Latin America Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Latin America Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93 Brazil Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 94 Brazil Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 95 Brazil Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 96 Brazil Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 97 Argentina Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 98 Argentina Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 99 Argentina Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 100 Argentina Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 101 MEA Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 102 MEA Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 103 MEA Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 104 MEA Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 105 MEA Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 106 South Africa Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 107 South Africa Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 108 South Africa Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 109 South Africa Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 UAE Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 115 UAE Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 116 UAE Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 117 UAE Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Peptide antibiotics market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Peptide antibiotics market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook, revenue, 2024 (USD Million)
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Peptide Antibiotics market driver impact
  • Fig. 14 Peptide antibiotics market restraint impact
  • Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 16 Industry Analysis - Porter's Five Forces
  • Fig. 17 Peptide antibiotics market: Product outlook and key takeaways
  • Fig. 18 Peptide antibiotics market: Product movement analysis & market share 2024 & 2030
  • Fig. 19 Ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Non-ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Peptide Antibiotics market: Disease outlook and key takeaways
  • Fig. 22 Peptide Antibiotics market: Disease movement analysis & market share 2024 & 2030
  • Fig. 23 Skin infection market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 HABP/VABP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Blood stream infections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Peptide antibiotics market: Route of administration outlook and key takeaways
  • Fig. 28 Peptide antibiotics market: Route of administration movement analysis & market share 2024 & 2030
  • Fig. 29 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Peptide antibiotics market: Distribution channel outlook and key takeaways
  • Fig. 34 Peptide antibiotics market: Distribution channel movement analysis & market share 2024 & 2030
  • Fig. 35 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Global peptide antibiotics market: Regional movement analysis
  • Fig. 39 Global peptide antibiotics market: Regional outlook and key takeaways
  • Fig. 40 Global peptide antibiotics market share and leading players
  • Fig. 41 North America, by country
  • Fig. 42 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. key country dynamics
  • Fig. 44 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Canada key country dynamics
  • Fig. 46 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Mexico key country dynamics
  • Fig. 48 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UK key country dynamics
  • Fig. 51 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Germany key country dynamics
  • Fig. 53 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 France key country dynamics
  • Fig. 55 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Italy key country dynamics
  • Fig. 57 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Spain key country dynamics
  • Fig. 59 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Denmark key country dynamics
  • Fig. 61 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Sweden key country dynamics
  • Fig. 63 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Norway key country dynamics
  • Fig. 65 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 China key country dynamics
  • Fig. 68 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Japan key country dynamics
  • Fig. 70 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 India key country dynamics
  • Fig. 72 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Thailand key country dynamics
  • Fig. 74 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 South Korea key country dynamics
  • Fig. 76 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Australia key country dynamics
  • Fig. 78 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Brazil key country dynamics
  • Fig. 81 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Argentina key country dynamics
  • Fig. 83 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 South Africa key country dynamics
  • Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Saudi Arabia key country dynamics
  • Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 UAE key country dynamics
  • Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Kuwait key country dynamics
  • Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Market share Analysis of key market players, 2024